Technology
Health
Biotechnology

ProQR Therapeutics

$14.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-0.40%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PRQR and other stocks, options, ETFs, and crypto commission-free!

About

ProQR Therapeutics N.V. Ordinary Shares, also called ProQR Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Read More Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Employees
140
Headquarters
Leiden, Zuid-Holland
Founded
2012
Market Cap
649.41M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
272.83K
High Today
$15.21
Low Today
$14.84
Open Price
$14.99
Volume
101.88K
52 Week High
$24.00
52 Week Low
$2.90

Collections

Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2014 IPO
Europe (Non-UK)

News

MarketBeatFeb 21

Stock Price, News, & Analysis for ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.

80

Earnings

-$0.55
-$0.39
-$0.24
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.